Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Notes Payables: 2014-2017

Historic Notes Payables for Viking Therapeutics (VKTX) over the last 4 years, with Dec 2017 value amounting to $3.5 million.

  • Viking Therapeutics' Notes Payables was N/A to $3.7 million in Q1 2018 from the same period last year, while for Mar 2018 it was $3.7 million, marking a year-over-year change of. This contributed to the annual value of $3.5 million for FY2017, which is 5.55% up from last year.
  • Latest data reveals that Viking Therapeutics reported Notes Payables of $3.5 million as of FY2017, which was up 5.55% from $3.3 million recorded in FY2016.
  • Viking Therapeutics' Notes Payables' 5-year high stood at $3.5 million during FY2017, with a 5-year trough of $304,274 in FY2014.
  • In the last 3 years, Viking Therapeutics' Notes Payables had a median value of $3.3 million in 2016 and averaged $3.1 million.
  • Data for Viking Therapeutics' Notes Payables shows a peak YoY spiked of 721.63% (in 2015) over the last 5 years.
  • Yearly analysis of 4 years shows Viking Therapeutics' Notes Payables stood at $304,274 in 2014, then soared by 721.63% to $2.5 million in 2015, then soared by 30.78% to $3.3 million in 2016, then climbed by 5.55% to $3.5 million in 2017.